美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Odyssey Therapeutics

16.42

-1.5800-8.78%

盘后：16.00-0.4200-2.56%16:52 EDT

成交量：317.04万

成交额：5,605.44万

市值：7.39亿

市盈率：-5.22

高：20.30

开：20.00

低：15.35

收：18.00

52周最高：20.30

52周最低：15.35

股本：4,499.48万

流通股本：1,324.00万

量比：- -

换手率：23.95%

股息：- -

股息率：- -

每股收益(TTM):-3.1460

净资产收益率：-85.50%

总资产收益率：-41.66%

市净率：-1.51

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Odyssey Therapeutics

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://odysseytx.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Odyssey Therapeutics, Inc.于2021年4月在特拉华州注册成立。Odyssey是一家临床阶段的生物制药公司，由一个寻求改变自身免疫性和炎症性疾病患者护理标准的药物猎手团队和董事会领导。为了实现这一目标，该公司正在开发旨在精确针对疾病病理的药物，最初的重点是先天免疫系统。该公司相信，他们对免疫生物学的深刻理解，加上在药物、计算和蛋白质化学、结构生物学、遗传学和药理学方面的领先专业知识，使他们能够识别和药物驱动疾病的关键信号节点。

董事

名称

职位

Gary D. Glick

Chief Executive Officer and Director and President

Carolyn Ng

Independent Director

Ian F. Smith

Independent Director

Jeffrey M. Leiden

Chair and Independent Director

Ksenija Pavletic

Independent Director

Nan Li

Independent Director

Nia Tatsis

Independent Director

Paulina Hill

Independent Director

Shelley Chu

Independent Director

Timothy P. Walbert

Independent Director

Valerie Odegard

Independent Director

股东

名称

职位

Gary D. Glick

Chief Executive Officer and Director and President

Collin Todd

Senior Vice President, Strategy and Business Development

Jason Haas

Chief Financial Officer

Anthony Opipari

Executive Vice President, Translational Medicine and Interim Chief Medical Officer

Jolie M. Siegel

Executive Vice President and General Counsel and Secretary

Natalie Dales

Chief of Research Operations and Portfolio Strategy

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ODTX/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ODTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODTX\",,,,,undefined,":{"symbol":"ODTX","market":"US","secType":"STK","nameCN":"Odyssey Therapeutics","latestPrice":16.42,"timestamp":1778270400000,"preClose":18,"halted":0,"volume":3170409,"hourTrading":{"tag":"盘后","latestPrice":16,"preClose":16.42,"latestTime":"16:52 EDT","volume":8486,"amount":141518.951416,"timestamp":1778273548200,"change":-0.42,"changeRate":-0.025579,"amplitude":0.043788},"delay":0,"changeRate":-0.08777777777777768,"floatShares":13240000,"shares":44994769,"eps":-3.146,"marketStatus":"盘后交易","change":-1.58,"latestTime":"05-08 16:55:00 EDT","open":20,"high":20.3,"low":15.35,"amount":56054422.665318005,"amplitude":0.275,"askPrice":16.71,"askSize":500,"bidPrice":15.5,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-3.146,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1778284800000},"marketStatusCode":4,"adr":0,"listingDate":1778212800000,"exchange":"NASDAQ","adjPreClose":18,"postHourTrading":{"tag":"盘后","latestPrice":16,"preClose":16.42,"latestTime":"16:52 EDT","volume":8486,"amount":141518.951416,"timestamp":1778273548200,"change":-0.42,"changeRate":-0.025579,"amplitude":0.043788},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODTX\",,,,,undefined,":{"symbol":"ODTX","floatShares":13240000,"roa":"-41.66%","roe":"-85.50%","lyrEps":0,"shares":44994769,"dividePrice":0,"high":20.3,"amplitude":0.275,"preClose":18,"low":15.35,"week52Low":15.35,"pbRate":"-1.51","psRate":"248.26","week52High":20.3,"institutionHeld":0,"latestPrice":16.42,"committee":-0.996008,"eps":-3.146,"divideRate":0,"volume":3170409,"delay":0,"ttmEps":-3.146,"open":20,"prevYearClose":18,"prevWeekClose":18,"prevMonthClose":18,"prevQuarterClose":18,"fiveDayClose":18,"twentyDayClose":18,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ODTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ODTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ODTX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://odysseytx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.1098},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.0903},{"period":"1year","weight":0.3037},{"period":"ytd","weight":0.0728}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Odyssey Therapeutics, Inc.于2021年4月在特拉华州注册成立。Odyssey是一家临床阶段的生物制药公司，由一个寻求改变自身免疫性和炎症性疾病患者护理标准的药物猎手团队和董事会领导。为了实现这一目标，该公司正在开发旨在精确针对疾病病理的药物，最初的重点是先天免疫系统。该公司相信，他们对免疫生物学的深刻理解，加上在药物、计算和蛋白质化学、结构生物学、遗传学和药理学方面的领先专业知识，使他们能够识别和药物驱动疾病的关键信号节点。","exchange":"NASDAQ","name":"Odyssey Therapeutics","nameEN":"Odyssey Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ODTX\",market:\"US\",,,undefined,":{"directors":[{"name":"Gary D. Glick","position":"Chief Executive Officer and Director and President"},{"name":"Carolyn Ng","position":"Independent Director"},{"name":"Ian F. Smith","position":"Independent Director"},{"name":"Jeffrey M. Leiden","position":"Chair and Independent Director"},{"name":"Ksenija Pavletic","position":"Independent Director"},{"name":"Nan Li","position":"Independent Director"},{"name":"Nia Tatsis","position":"Independent Director"},{"name":"Paulina Hill","position":"Independent Director"},{"name":"Shelley Chu","position":"Independent Director"},{"name":"Timothy P. Walbert","position":"Independent Director"},{"name":"Valerie Odegard","position":"Independent Director"}],"executives":[{"name":"Gary D. Glick","position":"Chief Executive Officer and Director and President"},{"name":"Collin Todd","position":"Senior Vice President, Strategy and Business Development"},{"name":"Jason Haas","position":"Chief Financial Officer"},{"name":"Anthony Opipari","position":"Executive Vice President, Translational Medicine and Interim Chief Medical Officer"},{"name":"Jolie M. Siegel","position":"Executive Vice President and General Counsel and Secretary"},{"name":"Natalie Dales","position":"Chief of Research Operations and Portfolio Strategy"}]}}}